Literature DB >> 29599842

Therapeutic effects of simvastatin combined with kallistatin treatment for pediatric burn patients with sepsis.

Yefeng Dai1, Xufei Zhao1.   

Abstract

The aim of the present study was to examine the combined efficacy of simvastatin and kallistatin treatment for pediatric burn sepsis. A total of 72 pediatric patients with burn sepsis were recruited and randomly divided into 3 groups, receiving simvastatin (40 mg/day), kallistatin (20 mg/day) or combined treatment. ELISA, reverse transcription-quantitative polymerase chain reaction, western blotting and flow cytometry were used to analyze the therapeutic effects of simvastatin and kallistatin. The results revealed that combined treatment in pediatric burn sepsis patients decreased the inflammatory cytokine tumor necrosis factor α and interleukin (IL)-1β serum levels, whereas it increased IL-10 and human leukocyte antigen-D related levels. In addition, administration of combined simvastatin and kallistatin decreased the blood urea nitrogen and serum creatinine levels in the patients. It was also demonstrated that Toll-like receptor 4 expression on the surface of monocytes was markedly decreased, while suppressor of cytokine signaling-3 expression was increased in the combined treatment group as compared with the kallistatin or simvastatin treatment alone. Combined treatment also promoted human endothelial cell (HEC) growth compared with the single treatment groups and inhibited the high mobility group box-1 (HMGB1) levels, HMGB1-induced nuclear factor-κB activation and inflammatory gene expression levels in these cells. The study further demonstrated that combined treatment significantly decreased HEC apoptosis through the upregulation of B-cell lymphoma 2 (Bcl-2) and P53 expression levels, as well as downregulation of Bcl-2-associated X protein and caspase-3 levels. In conclusion, these observations indicated that combined treatment with simvastatin and kallistatin inhibited HEC apoptosis, which may be a potential therapeutic strategy for the treatment of pediatric burn sepsis patients.

Entities:  

Keywords:  apoptosis; human endothelial cells; inflammation; kallistatin; pediatric burn sepsis; simvastatin

Year:  2018        PMID: 29599842      PMCID: PMC5867412          DOI: 10.3892/etm.2018.5791

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  38 in total

1.  [Influence of simvastatin treatment on Toll-like receptor 4 in monocytes of peripheral blood in patients with sepsis and severe sepsis].

Authors:  Huanzhang Shao; Cunzhen Wang; Wenliang Zhu; Xiaopei Huang; Zhisong Guo; Huifeng Zhang; Bingyu Qin
Journal:  Zhonghua Wei Zhong Bing Ji Jiu Yi Xue       Date:  2016-02

2.  Measurement of NF-κB transcriptional activity and identification of NF-κB cis-regulatory elements using luciferase assays.

Authors:  Patricia E Collins; Christine O'Carroll; Ruaidhrí J Carmody
Journal:  Methods Mol Biol       Date:  2015

3.  Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation.

Authors:  Julie Chao; Hang Yin; Yu-Yu Yao; Bo Shen; Robert S Smith; Lee Chao
Journal:  Hum Gene Ther       Date:  2006-12       Impact factor: 5.695

4.  ANTERIOR CHAMBER FLARE DURING BEVACIZUMAB TREATMENT IN EYES WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION.

Authors:  Asta Hautamäki; Arto Luoma; Ilkka Immonen
Journal:  Retina       Date:  2016-11       Impact factor: 4.256

5.  The Spectrum of Pediatric Sepsis: "Septicemia" Misses Severe Cases.

Authors:  Halden F Scott; Raina Paul; Fran Balamuth
Journal:  Ann Emerg Med       Date:  2015-12       Impact factor: 5.721

Review 6.  Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit?

Authors:  K Alun Brown; Geraint A Brown; Sion M Lewis; Richard Beale; David F Treacher
Journal:  Int Immunopharmacol       Date:  2016-05-19       Impact factor: 4.932

7.  Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Amanda M Jones; Patricia A Julien-Williams; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

8.  Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis.

Authors:  Sang Kyu Lee; Yong Chan Kim; Seok Bean Song; Young Sang Kim
Journal:  Biochem Biophys Res Commun       Date:  2009-12-30       Impact factor: 3.575

9.  Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress.

Authors:  Bo Shen; Makoto Hagiwara; Yu-Yu Yao; Lee Chao; Julie Chao
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis.

Authors:  Pengfei Li; Youming Guo; Grant Bledsoe; Zhi-Rong Yang; Hongkuan Fan; Lee Chao; Julie Chao
Journal:  Crit Care       Date:  2015-05-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.